Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bio-Path Holdings (BPTH)

Bio-Path Holdings (BPTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Bio-Path Holdings, Inc. Expands DNAbilize® Technology to Obesity Treatment, Reveals Third Quarter Financial Results

Bio-Path Holdings reports Q3 2024 results, initiating obesity program, advancing oncology trials, and closing a $4M private placement.Quiver AI SummaryBio-Path Holdings, Inc. has expanded its DNAbilize®...

BPTH : 0.8700 (+8.89%)
Bio-Path: Q3 Earnings Snapshot

Bio-Path: Q3 Earnings Snapshot

BPTH : 0.8700 (+8.89%)
Bio-Path Holdings Reports Third Quarter 2024 Financial Results

BPTH : 0.8700 (+8.89%)
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

BPTH : 0.8700 (+8.89%)
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BPTH : 0.8700 (+8.89%)
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BPTH : 0.8700 (+8.89%)
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity

BPTH : 0.8700 (+8.89%)
Bio-Path: Q2 Earnings Snapshot

Bio-Path: Q2 Earnings Snapshot

BPTH : 0.8700 (+8.89%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

ATNM : 1.4600 (-0.68%)
BPTH : 0.8700 (+8.89%)
LGVN : 1.8500 (-1.07%)
SLS : 1.1850 (-2.87%)
BMY : 58.14 (-0.15%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

ATNM : 1.4600 (-0.68%)
BPTH : 0.8700 (+8.89%)
LGVN : 1.8500 (-1.07%)
SLS : 1.1850 (-2.87%)
BMY : 58.14 (-0.15%)

Barchart Exclusives

Disney Stock: Is DIS Still a Buy after Rallying 18% in a Month?
Disney shares have risen considerably since the company released its fiscal Q4 2024 earnings earlier this month. The stock has room to run higher into 2025 also, given its growth prospects and reasonable valuations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar